15-min delayed · Jul 28, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 7 firms covering Corbus Pharmaceuticals Holding, 7 rate it Buy or better, 0 sit at Hold, and 0 rate it Sell or worse, a moderate buy consensus. Targets span $30.00 to $53.00, a moderate spread. The average target of $41.00 sits 352% above the current $9.08. The rating mix has stayed broadly stable, with Buy-side ratings edging up from 5 to 7 over recent months. On the fundamentals, the Street sees consensus EPS building from about $-1.03 next quarter toward $-5.08 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS7 ratings
Moderate Buy
Strong Buy00%
Buy7100%
Hold00%
Sell00%
Strong Sell00%
Based on 7 analysts giving stock ratings to Corbus Pharmaceuticals Holding.
As of Jul, 7 of 7 firms rate CRBP a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
CRBP EPS & revenue forecast
EPS · NEXT QUARTER
$-1.03
Range $-1.49 – $-0.63 · 10 analysts · -46% YoY
Next period, 10 analysts expect Corbus Pharmaceuticals Holding to earn $-1.03 a share (range $-1.49 – $-0.63), versus $-1.90 a year earlier. Full-year consensus is $-4.57, growing to $-5.08 the year after.
REVENUE · NEXT QUARTER
$1.1M
Range $0 – $10.0M · 10 analysts
Revenue is expected to reach $1.1M (range $0 – $10.0M). Full-year consensus is $1.1M, rising to $2.4M next year.
Top analysts covering Corbus Pharmaceuticals Holding
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on CRBP.
#1
Andrew Fein
HC Wainwright & Co. · Rank #35
Buy
$75.00+726.0% to target
Overall win rate
46%
+ Follow
#2
Jeff Jones
Oppenheimer · Rank #197
Buy
$52.00+472.7% to target
Overall win rate
34%
+ Follow
#3
Andres Y. Maldonado
HC Wainwright & Co. · Rank #211
Buy
$40.00+340.5% to target
Overall win rate
38%
+ Follow
#4
Leland Gershell
Oppenheimer · Rank #254
Buy
$54.00+494.7% to target
Overall win rate
37%
+ Follow
#5
Brian Abrahams
RBC Capital · Rank #311
Buy
$36.00+296.5% to target
Overall win rate
25%
+ Follow
CRBP stock forecast FAQ
What is CRBP's average 12-month price target?+
The 7 analysts with a live target average $41.00 for Corbus Pharmaceuticals Holding over the next 12 months, ranging from a $53.00 high to a $30.00 low.
Is CRBP stock a Buy, Sell or Hold right now?+
The current consensus is Moderate Buy. Of the 7 analyst ratings, 7 are Buy or Strong Buy, 0 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for CRBP?+
The Street-high target is $53.00 (RBC Capital), and the Street-low is $30.00 (Wedbush). The average of all 7 active targets is $41.00.
How many Wall Street analysts cover CRBP?+
7 analysts have an active rating on Corbus Pharmaceuticals Holding, and 7 firms carry a live 12-month price target.
Who is the most accurate analyst covering CRBP?+
Among analysts who currently cover CRBP, Andrew Fein of HC Wainwright & Co. has the strongest overall Quantellect track record (Rank #35). Their current call is Buy with a $75.00 target.
What is Corbus Pharmaceuticals Holding's projected EPS for next quarter?+
The consensus estimate is $-1.03 per share (range $-1.49 – $-0.63) across 10 analysts. Full-year EPS is projected at $-4.57, rising to $-5.08 the following year.
How much revenue is Corbus Pharmaceuticals Holding expected to report next quarter?+
Consensus revenue is $1.1M (range $0 – $10.0M). Full-year revenue is projected at $1.1M, growing to $2.4M next year.
Have analysts been upgrading or downgrading CRBP lately?+
As of Jul, 7 of 7 firms rate CRBP a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their CRBP calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
